The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AKTX | -73.99% | -99.34% | -63.36% | -100% |
| S&P | +16.49% | +84.25% | +12.99% | +263% |
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $32.94M | -8.1% |
| Market Cap / Employee | $3.66M | 0.0% |
| Employees | 9 | 0.0% |
| Net Income | -$6,361.56K | -119.7% |
| EBITDA | -$2,210.64K | -19.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.54M | 13.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $2.12M | 76.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -65.35% | 0.0% |
| Return On Invested Capital | 558.89% | 44326.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,101.65K | -41.1% |
| Operating Free Cash Flow | -$2,101.65K | -41.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.21 | -2.25 | 1.55 | 1.29 | -113.30% |
| Price to Tangible Book Value | -2.21 | -2.25 | -1.31 | -1.50 | -84.53% |
| Enterprise Value to EBITDA | -7.77 | -9.38 | -11.28 | -14.73 | -21.89% |
| Return on Equity | -196.7% | -111.9% | -196.6% | - | |
| Total Debt | $3.26M | $1.85M | $1.55M | $2.12M | 76.42% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
